Single-cell analysis of metabolic pathway activity of tumor-infiltrating immune cells in combination therapy compared with anti-CTLA-4 antibody. The bar graph shows normalized pathway enrichment score differences for each particular cell type, which are calculated by subtracting the median pathway enrichment score in the anti-CTLA-4 from that of the combination therapy. (A–C) Hallmark and KEGG analysis of differential pathway activities in a combination therapy group (A) CD4 Teff cells, (B) CD8 T cells, and (C) macrophages.